Skip to content
2000
Volume 21, Issue 1
  • ISSN: 1573-4056
  • E-ISSN: 1875-6603

Abstract

Objective

This study aimed to determine the relationship between Radiation-Induced Lung Injury (RILI) and the clinical outcome of Non-Small Cell Lung Cancer (NSCLC) following Stereotactic Ablative Radiotherapy (SABR).

Methods

Clinical data and follow-up CT scanning of 101 patients with early NSCLC who received SABR treatment from January 2012 to December 2018 were retrospectively collected, and the Progression Free Survival (PFS) was calculated. CT features of peritumoral RILI were observed by 3 radiologists, each with 10 to 15 years of experience, based on consensus among 3 radiologists and divided into 3 types. Type 1: Diffuse consolidation surrounding the tumor, including the tumor boundary. Type 2: Ground Glass Opacities (GGOs) covering more than 180 degrees around the tumor. Type 3: GGOs surrounding the tumor but covering less than 180 degrees. Log-rank test was used to analyze the correlation between the classification of radiation-induced lung injury CT findings and PFS. Independent predictors of PFS rate were analyzed by COX multivariate regression.

Results

The 5-year PFS rates based on RILI types observed at 6-8 months post-SABR were: Type 1 = 69.5%, Type 2 = 50.9%, and Type 3 = 36.1%. A statistically significant difference was observed among the three RILI types (p=0.025). COX multivariate regression analysis showed that RILI were independent factors influencing PFS (at 6-8 months follow-up after radiotherapy (p=0.041).

Conclusion

Patients with more extensive and denser RILI tend to have a longer PFS. Data from our cohort study indicate that the 6- 8 months post-SABR period represents the optimal follow-up window, as evidenced by significant progression-free survival rate dynamics during this interval (HR = 1.5, 95% CI 1.0-2.2, p < 0.05).

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056388161250320055401
2025-04-09
2025-10-31
Loading full text...

Full text loading...

/deliver/fulltext/cmir/21/1/CMIR-21-E15734056388161.html?itemId=/content/journals/cmir/10.2174/0115734056388161250320055401&mimeType=html&fmt=ahah
/content/journals/cmir/10.2174/0115734056388161250320055401
Loading
/content/journals/cmir/10.2174/0115734056388161250320055401
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test